ArticlePloS one2026
Pre-CRRT furosemide and mortality in sepsis-associated AKI: A retrospective cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to assess whether pre-CRRT furosemide use in SAKI patients requiring CRRT is associated with 28-day mortality, and to evaluate its relationship with secondary outcomes including short-term mortality, in-hospital death, and length of stay. We also examined potential effect modification by CKD status and furosemide dosage.
designRetrospective cohort study.
settingData were extracted from the MIMIC-IV database, a large publicly available critical care database.
participantsA total of 969 adult patients with SAKI requiring CRRT were included.
interventionPatients were stratified based on pre-CRRT furosemide use (defined as administration within 72 hours prior to CRRT initiation). Propensity score matching (1:1) was applied to generate balanced cohorts (n = 560). MEASUREMENTS: Primary outcome: 28-day all-cause mortality. Secondary outcomes: 7-day mortality, 90-day mortality, in-hospital mortality, and length of ICU and hospital stay. Multivariable Cox regression was used to adjust for potential confounders.
resultsIn the matched analysis, furosemide use was associated with significantly lower 28-day mortality (44.3% vs 58.6%; HR 0.58, 95% CI 0.46-0.73, p < 0.001). Consistent reductions were observed in 7-day mortality (HR 0.45), 90-day mortality (HR 0.59), and in-hospital mortality (HR 0.50; all p < 0.01). Subgroup analyses showed greater benefit in non-chronic kidney disease patients (interaction p = 0.021) and with high-dose furosemide (>90mg/72h; HR 0.62, 95% CI 0.45-0.85). Sensitivity analyses in the full cohort confirmed robustness (HR 0.59, 95% CI 0.49-0.72). The use of furosemide is related to the prolongation of CRRT startup time (1.52 vs 1.46 days). However, furosemide use was associated with prolonged median ICU stay (9.3 vs 6.1 days) and hospital stay (20.8 vs 12.5 days).
conclusionsThese findings suggest that, in this selected cohort, pre-CRRT furosemide use was associated with lower mortality and does not appear to be associated with harm from delayed CRRT initiation. However, due to the observational design, these results should be warrant confirmation in prospective, randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.